DoseMe Expands Precision Dosing Leadership with Strategic Acquisition of Firstline to Deliver Comprehensive Clinical Decision Support in the Global Fight Against Infectious Diseases
DoseMe, a global leader in model-informed precision dosing (MIPD) software and a portfolio company of Fairlong Capital, has announced its acquisition of Firstline, a premier clinical decision support platform that delivers localized, evidence-based infectious disease treatment guidance to healthcare professionals worldwide. This acquisition marks a major milestone in DoseMe’s mission to revolutionize the delivery of personalized medicine by integrating advanced dosing technology with infectious disease management and antimicrobial stewardship (AMS) tools.
By combining DoseMe’s sophisticated precision dosing platform with Firstline’s globally recognized decision support capabilities, the newly unified organization will create a single, connected digital ecosystem that empowers clinicians to make faster, more effective patient care decisions—from therapy selection to individualized dosing optimization.
A Transformational Partnership for Clinical Decision Support
The acquisition unites two highly complementary platforms that address critical needs across the continuum of patient care. Firstline’s software, widely adopted by hospitals, health systems, and public health organizations—including partnerships with government agencies and the World Health Organization—delivers timely access to infectious disease treatment protocols, antimicrobial resistance data, and local prescribing guidance.
DoseMe, on the other hand, brings precision to the dosing process itself. Its model-informed precision dosing platform applies advanced pharmacokinetic and pharmacodynamic (PK/PD) models to tailor dosing recommendations based on patient-specific characteristics such as weight, age, renal function, and drug concentrations. Together, the platforms create an end-to-end clinical decision support system that not only guides clinicians toward the right therapeutic choice but also ensures that each patient receives the most effective and safest possible dose.
“Firstline is the perfect complement to DoseMe with proven value that provides impact on patient outcomes, hospital ecology, and combating antimicrobial resistance,” said Paul Edwards, CEO of DoseMe. “Together, we support antimicrobial stewardship initiatives and accelerate optimized patient care decisions by helping clinicians access local stewardship protocols and translate them directly into personalized precision dosing.”
This integration positions DoseMe to deliver what healthcare systems have long sought—a comprehensive, point-of-care solution that bridges the gap between clinical policy and patient-level execution.
Addressing the Growing Threat of Antimicrobial Resistance
Antimicrobial resistance (AMR) has emerged as one of the most urgent global health challenges of the 21st century. The Centers for Disease Control and Prevention (CDC) estimates that antibiotic-resistant infections account for tens of thousands of deaths annually in the United States alone and place a staggering economic burden on the healthcare system. In total, these infections are estimated to cost the U.S. between $21 billion and $34 billion each year, while contributing to more than 8 million excess hospital days.
At the heart of this problem is the misuse and overuse of antibiotics—issues that antimicrobial stewardship programs aim to address through education, local guidelines, and real-time decision support. However, many health systems struggle to operationalize these programs effectively at the bedside. Clinicians often face fragmented information systems that make it difficult to align treatment decisions with institutional protocols or regional resistance patterns.
The integration of Firstline and DoseMe seeks to overcome these barriers by offering clinicians a unified platform that translates complex stewardship policies into actionable, patient-specific guidance at the point of care. Through this combination, hospitals can not only enhance the quality of care but also reduce variability in antibiotic use, decrease resistance development, and improve overall outcomes.
Firstline’s Global Reach and Proven Value
Founded with the goal of democratizing access to infectious disease knowledge, Firstline has grown into a trusted decision support resource used by hospitals, governments, and public health organizations around the world. Its cloud-based platform delivers localized clinical guidelines, treatment algorithms, and antimicrobial susceptibility data in an easy-to-use mobile and web interface.
By connecting clinicians to their institution’s specific protocols, Firstline ensures that care is consistent, evidence-based, and responsive to local resistance patterns. The platform’s integration with public health systems has also made it a valuable tool for national and regional stewardship initiatives.
“We’re immensely proud to have built Firstline into an organization delivering clinical guidance globally to hospitals, governments, and the World Health Organization,” said Dr. Michael Long, co-founder and Chief Clinical Officer of Firstline. “We’re excited to see Firstline continue to flourish as part of the larger DoseMe organization.”
This acquisition not only expands DoseMe’s global footprint but also extends its reach into new clinical settings where stewardship and dosing optimization can significantly improve patient outcomes.
Creating an End-to-End Solution for Personalized Medicine
The combination of DoseMe and Firstline creates a powerful synergy that aligns with healthcare’s accelerating shift toward personalized medicine and value-based care. By integrating guideline-based decision support with individualized dosing intelligence, the joint platform delivers a complete workflow solution for clinicians managing complex infectious diseases.
From the moment a clinician selects a treatment regimen using Firstline’s evidence-based guidance, they can transition seamlessly into DoseMe’s precision dosing module to calculate an optimal dose tailored to the individual patient. This closed-loop process minimizes guesswork, shortens the time to effective therapy, and reduces risks of under- or overdosing.
Health systems that adopt this integrated approach can expect measurable benefits, including:
- Improved patient safety through precision-guided dosing recommendations.
- Reduced resistance development by aligning antimicrobial use with local stewardship strategies.
- Lower healthcare costs driven by decreased hospital stays, readmissions, and adverse events.
- Enhanced compliance with institutional AMS policies and regulatory requirements.
By uniting these strengths, the DoseMe–Firstline platform is set to redefine what comprehensive clinical decision support looks like for infectious disease management.
Investment and Vision for the Future
Fairlong Capital, DoseMe’s majority investor, views this acquisition as a pivotal step in the company’s long-term growth and strategic vision. The firm has backed DoseMe’s expansion as part of its broader commitment to scalable healthcare technologies that improve patient outcomes through data-driven insights and precision tools.
“The combination of DoseMe and Firstline advances the mission to address the full patient care continuum of personalized medicine,” said David Neiman, Managing Partner at Fairlong Capital. “We look forward to the consolidated business’s continued growth—but most importantly, to the profound impact this combination will have on the customer’s ability to improve patient care.”
As part of the integration, DoseMe plans to retain and expand the Firstline team to ensure continuity for its existing partners and users while accelerating product innovation. Together, the two organizations will continue to collaborate with health systems, governments, and global health agencies to develop new capabilities that make precision dosing and antimicrobial stewardship more accessible and actionable.
A New Era in Precision Dosing and Stewardship
The acquisition comes at a time when the healthcare industry is increasingly focused on integrating artificial intelligence, real-world data, and predictive analytics into clinical workflows. DoseMe’s MIPD technology, powered by advanced Bayesian modeling, exemplifies this movement by transforming complex pharmacological science into simple, intuitive tools for everyday clinical use.
With the addition of Firstline’s decision support and guideline delivery infrastructure, DoseMe is now uniquely positioned to deliver a unified digital solution that connects global knowledge, local data, and patient-specific insights—all in real time.
For clinicians on the frontlines of infectious disease management, this integration means having a single source of truth: a trusted, continuously updated, and fully interoperable system that supports every step of the treatment decision process.
For patients, it promises faster, safer, and more effective care.
And for the global healthcare community, it represents a significant leap forward in the collective fight against antimicrobial resistance.
Media Contact:
- DoseMe Health: hello@dosemehealth.com
- Firstline: press@firstline.org
About DoseMe
DoseMe combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPAA compliant and the only Bayesian dosing platform that is both HITRUST CSF R2 and ISO 13485 certified. For more information on successful applications of its products, DoseMeRx and DoseMe Analytics, visit https://doseme-rx.com/success-stories
About Firstline
Firstline is a mobile-first clinical decision support platform designed to make infectious disease protocols accessible to every clinician, anywhere. Trusted by leading healthcare organizations worldwide, Firstline reduces antibiotic overuse, improves adherence to stewardship guidance, and provides clinicians with fast, reliable access to local resistance data. For more information, visit: Firstline – Clinical Decision Support Platform
About Fairlong Capital LLC
Fairlong Capital is a middle-market private equity firm focused on value investments in partnership with institutional and strategic investors across a variety of industries. Fairlong partners with management teams to offer flexible capital solutions to companies across a variety of industries, including healthcare, technology, industrials, business & financial services, building and forest products, power and energy, among others.
Source Link: https://www.businesswire.com/
